Over subsequent decades, extensive research using the Fmr1 KO model identified deficits in receptors, signaling pathways, and downstream targets, advancing our understanding of FXS pathophysiology and driving the development of potential therapeutics [17,18,19,20,21,22,23]. Here, FMR1 is linked to fragile X syndrome.